|
US5997864A
(en)
|
1995-06-07 |
1999-12-07 |
Novo Nordisk A/S |
Modified factor VII
|
|
US20040087498A1
(en)
*
|
1991-02-28 |
2004-05-06 |
Novo Nordisk Health Care Ag |
Modified factor VII
|
|
EP1005361B1
(en)
*
|
1997-07-18 |
2010-01-06 |
Novo Nordisk Health Care AG |
USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ENDOTHELIAL DYSFUNKTION AND FOR THE INHIBITION OF ANGIOGENESIS RESPECTIVELY
|
|
US7247708B2
(en)
|
1997-10-23 |
2007-07-24 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US6747003B1
(en)
|
1997-10-23 |
2004-06-08 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US6693075B1
(en)
*
|
1997-10-23 |
2004-02-17 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US6406488B1
(en)
*
|
1998-08-27 |
2002-06-18 |
Heartstent Corporation |
Healing transmyocardial implant
|
|
EP0987274A1
(en)
|
1998-09-15 |
2000-03-22 |
Hoechst Marion Roussel Deutschland GmbH |
Factor VIIa Inhibitors
|
|
EP1059302A1
(en)
|
1999-06-08 |
2000-12-13 |
Aventis Pharma Deutschland GmbH |
Factor VIIa inhibitors
|
|
US6924359B1
(en)
*
|
1999-07-01 |
2005-08-02 |
Yale University |
Neovascular-targeted immunoconjugates
|
|
EP1095933A1
(en)
|
1999-10-30 |
2001-05-02 |
Aventis Pharma Deutschland GmbH |
Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
|
|
PL204285B1
(pl)
*
|
2000-02-11 |
2009-12-31 |
Bayer Healthcare Llc |
Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
|
|
JP2003530838A
(ja)
*
|
2000-04-12 |
2003-10-21 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
アルブミン融合タンパク質
|
|
US7812132B2
(en)
|
2000-04-28 |
2010-10-12 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
US7220837B1
(en)
|
2000-04-28 |
2007-05-22 |
Regents Of The University Of Minnesota |
Modified vitamin K-dependent polypeptides
|
|
EP1162194A1
(en)
|
2000-06-06 |
2001-12-12 |
Aventis Pharma Deutschland GmbH |
Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
|
|
US6833357B2
(en)
*
|
2000-06-20 |
2004-12-21 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for modulating muscle cell and tissue contractility
|
|
US7160540B2
(en)
*
|
2000-06-30 |
2007-01-09 |
Regents Of The University Of Minnesota |
Methods for detecting activity of clottings factors
|
|
US6423826B1
(en)
|
2000-06-30 |
2002-07-23 |
Regents Of The University Of Minnesota |
High molecular weight derivatives of vitamin K-dependent polypeptides
|
|
US20030211094A1
(en)
|
2001-06-26 |
2003-11-13 |
Nelsestuen Gary L. |
High molecular weight derivatives of vitamin k-dependent polypeptides
|
|
AU3320602A
(en)
|
2000-12-06 |
2002-06-18 |
Aventis Pharma Gmbh |
Guanidine and amidine derivatives as factor xa inhibitors
|
|
US6825323B2
(en)
*
|
2001-01-10 |
2004-11-30 |
The United States Of America As Represented By The Secretary Of The Army |
Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
|
|
US7235638B2
(en)
|
2001-03-22 |
2007-06-26 |
Novo Nordisk Healthcare A/G |
Coagulation factor VII derivatives
|
|
CZ20032454A3
(en)
*
|
2001-03-22 |
2004-03-17 |
Novo Nordisk Health Care Ag |
Coagulation factor vii derivative
|
|
RU2003134701A
(ru)
*
|
2001-05-02 |
2005-03-27 |
Ново Нордиск А/С (DK) |
Модифицированный fvii при лечении ards
|
|
EP1270551A1
(en)
|
2001-06-26 |
2003-01-02 |
Aventis Pharma Deutschland GmbH |
Urea derivatives with antiproteolytic activity
|
|
AU2002326135A1
(en)
*
|
2001-09-10 |
2003-03-24 |
Florence Medical Ltd. |
Individual ffr determination for lesions of a multi-lesioned blood vessel
|
|
US7173003B2
(en)
|
2001-10-10 |
2007-02-06 |
Neose Technologies, Inc. |
Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
|
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
|
EP2305312B1
(en)
|
2001-10-10 |
2015-03-04 |
ratiopharm GmbH |
Remodelling and glycoconjugation of follicle-stimulating hormone (FSH)
|
|
AU2002336920A1
(en)
*
|
2001-11-02 |
2003-05-12 |
Novo Nordisk Health Care Ag |
Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
|
|
EP1314733A1
(en)
|
2001-11-22 |
2003-05-28 |
Aventis Pharma Deutschland GmbH |
Indole-2-carboxamides as factor Xa inhibitors
|
|
ES2325653T3
(es)
|
2001-12-21 |
2009-09-11 |
Novo Nordisk Health Care Ag |
Composicion liquida de polipeptidos del factor vii.
|
|
KR20040065278A
(ko)
*
|
2001-12-21 |
2004-07-21 |
노보 노르디스크 에이/에스 |
변경된 인자 ⅶ 폴리펩티드의 액체 조성물
|
|
JP2005530682A
(ja)
*
|
2001-12-21 |
2005-10-13 |
ノボ ノルディスク アクティーゼルスカブ |
修飾第ｖｉｉ因子ポリペプチドの液体組成物
|
|
BR0309576A
(pt)
*
|
2002-04-30 |
2005-02-09 |
Maxygen Holdings Ltd |
Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
|
|
US20040009918A1
(en)
*
|
2002-05-03 |
2004-01-15 |
Hanne Nedergaard |
Stabilised solid compositions of modified factor VII
|
|
AU2003223925A1
(en)
*
|
2002-05-03 |
2003-11-17 |
Novo Nordisk A/S |
Stabilised solid compositions of modified factor vii
|
|
CA2490342C
(en)
|
2002-06-21 |
2015-06-16 |
Novo Nordisk A/S |
Stabilised solid compositions of factor vii polypeptides
|
|
CA2502162C
(en)
*
|
2002-09-30 |
2014-04-15 |
Bayer Healthcare Llc |
Fvii or fviia variants having increased clotting activity
|
|
US7358268B2
(en)
|
2002-12-04 |
2008-04-15 |
Sanofi-Aventis Deutschland Gmbh |
Imidazole derivatives as factor Xa inhibitors
|
|
US7429581B2
(en)
|
2002-12-23 |
2008-09-30 |
Sanofi-Aventis Deutschland Gmbh |
Pyrazole-derivatives as factor Xa inhibitors
|
|
US20040176704A1
(en)
*
|
2003-03-04 |
2004-09-09 |
Stevens Timothy A |
Collection device adapted to accept cartridge for point of care system
|
|
CA2518327A1
(en)
*
|
2003-03-18 |
2004-09-30 |
Novo Nordisk Health Care Ag |
Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
|
|
AU2004221761B2
(en)
*
|
2003-03-20 |
2010-01-07 |
Bayer Healthcare Llc |
FVII or FVIIa variants
|
|
US7897734B2
(en)
*
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
|
EP1615945B1
(en)
|
2003-04-09 |
2011-09-28 |
BioGeneriX AG |
Glycopegylation methods and proteins/peptides produced by the methods
|
|
US20040202726A1
(en)
*
|
2003-04-10 |
2004-10-14 |
Deshay Samuel L. |
Topical blood pressure composition
|
|
US7317027B2
(en)
|
2003-05-19 |
2008-01-08 |
Sanofi-Aventis Deutschland Gmbh |
Azaindole-derivatives as factor Xa inhibitors
|
|
US7223780B2
(en)
|
2003-05-19 |
2007-05-29 |
Sanofi-Aventis Deutschland Gmbh |
Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
|
|
EP1479680A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
Azaindole derivatives as Factor Xa inhibitors
|
|
US7741341B2
(en)
|
2003-05-19 |
2010-06-22 |
Sanofi-Aventis Deutschland Gmbh |
Benzimidazole-derivatives as factor Xa inhibitors
|
|
EP1479675A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
Indazole-derivatives as factor Xa inhibitors
|
|
EP1479677A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
New indole derivatives as factor xa inhibitors
|
|
BRPI0409936A
(pt)
*
|
2003-05-23 |
2006-04-25 |
Novo Nordisk Healthcare Ag |
uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
|
|
US7029675B1
(en)
*
|
2003-06-04 |
2006-04-18 |
Shu-Wha Lin |
Hepsin antagonist and methods of use
|
|
DE602004025576D1
(de)
*
|
2003-06-19 |
2010-04-01 |
Bayer Healthcare Llc |
Varianten der faktor-vii- oder -viia-gla-domäne
|
|
ATE547114T1
(de)
|
2003-06-25 |
2012-03-15 |
Novo Nordisk Healthcare Ag |
Flüssige zusammensetzungen von factor vii polypeptiden
|
|
DE602004023848D1
(de)
*
|
2003-07-01 |
2009-12-10 |
Novo Nordisk Healthcare Ag |
Von factor vii polypeptiden
|
|
WO2005012484A2
(en)
|
2003-07-25 |
2005-02-10 |
Neose Technologies, Inc. |
Antibody-toxin conjugates
|
|
WO2005016365A2
(en)
*
|
2003-08-14 |
2005-02-24 |
Novo Nordisk Health Care Ag |
Liquid, aqueous pharmaceutical composition of factor vii polypeptides
|
|
US20080305992A1
(en)
|
2003-11-24 |
2008-12-11 |
Neose Technologies, Inc. |
Glycopegylated erythropoietin
|
|
ES2676644T3
(es)
*
|
2003-12-19 |
2018-07-23 |
Novo Nordisk Health Care Ag |
Composiciones estabilizadas de polipéptidos de factor VII
|
|
EP1568698A1
(en)
|
2004-02-27 |
2005-08-31 |
Aventis Pharma Deutschland GmbH |
Pyrrole-derivatives as factor Xa inhibitors
|
|
WO2006035060A2
(en)
*
|
2004-09-29 |
2006-04-06 |
Novo Nordisk Health Care Ag |
Purification of a bulk of a factor vii polypeptide by fractionated elution from an anion-exchange material
|
|
EP1814573B1
(en)
|
2004-10-29 |
2016-03-09 |
ratiopharm GmbH |
Remodeling and glycopegylation of fibroblast growth factor (fgf)
|
|
CA2593682C
(en)
|
2005-01-10 |
2016-03-22 |
Neose Technologies, Inc. |
Glycopegylated granulocyte colony stimulating factor
|
|
EP1871795A4
(en)
|
2005-04-08 |
2010-03-31 |
Biogenerix Ag |
COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
|
|
US20070105755A1
(en)
|
2005-10-26 |
2007-05-10 |
Neose Technologies, Inc. |
One pot desialylation and glycopegylation of therapeutic peptides
|
|
WO2007056191A2
(en)
|
2005-11-03 |
2007-05-18 |
Neose Technologies, Inc. |
Nucleotide sugar purification using membranes
|
|
US9187532B2
(en)
|
2006-07-21 |
2015-11-17 |
Novo Nordisk A/S |
Glycosylation of peptides via O-linked glycosylation sequences
|
|
US20100075375A1
(en)
|
2006-10-03 |
2010-03-25 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
|
CN101796063B
(zh)
|
2007-04-03 |
2017-03-22 |
拉蒂奥法姆有限责任公司 |
使用糖聚乙二醇化g‑csf的治疗方法
|
|
WO2008154639A2
(en)
|
2007-06-12 |
2008-12-18 |
Neose Technologies, Inc. |
Improved process for the production of nucleotide sugars
|
|
CN103497247A
(zh)
|
2008-02-27 |
2014-01-08 |
诺沃—诺迪斯克有限公司 |
缀合的因子viii分子
|
|
US8962563B2
(en)
|
2009-12-21 |
2015-02-24 |
Baxter International, Inc. |
TFPI inhibitors and methods of use
|
|
LT2379096T
(lt)
|
2008-12-19 |
2019-12-27 |
Baxalta GmbH |
Tfpi inhibitoriai ir vartojimo būdai
|
|
US20110046060A1
(en)
|
2009-08-24 |
2011-02-24 |
Amunix Operating, Inc., |
Coagulation factor IX compositions and methods of making and using same
|
|
EP2547355B1
(en)
|
2010-03-19 |
2017-01-11 |
Baxalta GmbH |
Tfpi inhibitors and methods of use
|
|
KR101294351B1
(ko)
*
|
2010-05-27 |
2013-08-07 |
동국대학교 산학협력단 |
뇌혈전 형광영상기술을 이용한 뇌졸중 동물모델의 뇌경색 영역의 크기 예측 방법
|
|
CN111548418A
(zh)
|
2012-02-15 |
2020-08-18 |
比奥贝拉蒂治疗公司 |
因子viii组合物及其制备和使用方法
|
|
NZ628014A
(en)
|
2012-02-15 |
2016-09-30 |
Biogen Ma Inc |
Recombinant factor viii proteins
|
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
|
US20180207292A1
(en)
*
|
2015-07-22 |
2018-07-26 |
Iconic Therapeutics, Inc. |
Methods for treating disorders associated with angiogenesis and neovascularization
|
|
AU2016301303B2
(en)
|
2015-08-03 |
2021-10-07 |
Bioverativ Therapeutics Inc. |
Factor IX fusion proteins and methods of making and using same
|
|
ES2856968T3
(es)
|
2016-01-15 |
2021-09-28 |
Rigshospitalet |
Adquisición de imágenes de TEP cuantitativas de la expresión de factor tisular usando factor VII inhibido en el punto activo y marcado con 18F
|
|
WO2018091058A1
(en)
|
2016-11-17 |
2018-05-24 |
Rigshospitalet |
177-lu labeled active site inhibited factor vii
|
|
WO2018102743A1
(en)
|
2016-12-02 |
2018-06-07 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilic arthropathy using chimeric clotting factors
|
|
JP7763589B2
(ja)
|
2018-05-18 |
2025-11-04 |
バイオベラティブ セラピューティクス インコーポレイテッド |
血友病ａを処置する方法
|